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Background: Breast cancer risk is partially determined by several hormone-related factors. Preclinical and clinical
studies suggested that resveratrol may modulate these hormonal factors.
Methods: We conducted a pilot study in postmenopausal women with high body mass index (BMI ≥ 25 kg/m2) to
determine the clinical effect of resveratrol on systemic sex steroid hormones. Forty subjects initiated the resveratrol
intervention (1 gm daily for 12 weeks) with six withdrawn early due to adverse events (AEs). Thirty-four subjects
completed the intervention.
Results: Resveratrol intervention did not result in significant changes in serum concentrations of estradiol, estrone,
and testosterone but led to an average of 10% increase in the concentrations of sex steroid hormone binding
globulin (SHBG). Resveratrol intervention resulted in an average of 73% increase in urinary 2-hydroxyestrone (2-OHE1)
levels leading to a favorable change in urinary 2-OHE1/16α-OHE1 ratio. One participant had asymptomatic Grade 4
elevation of liver enzymes at the end of study intervention. Two subjects had Grade 3 skin rashes. The remaining
adverse events were Grade 1 or 2 events. The most common adverse events were diarrhea and increased total
cholesterol, reported in 30% and 27.5% of the subjects, respectively.
Conclusion: We conclude that among overweight and obese postmenopausal women, daily 1 gm dose of resveratrol
has favorable effects on estrogen metabolism and SHBG. Further placebo-controlled studies are needed to confirm our
findings on these hormone-related breast cancer risk factors and the attribution of the adverse effects observed in the
study population.
Trial registration: ClinicalTrials.gov: NCT01370889.
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Breast cancer risk is partially determined by several
hormone-related factors, and it has long been hypo-
thesized that high levels of endogenous hormones, espe-
cially estrogens, may increase breast cancer risk. After
menopause, ovarian production of estrogens has ceased.
The circulating estrogens are synthesized in the adipose
tissue by enzymatic aromatization of androgenic precur-
sors. Estrogen synthesis in adipose tissue is not regulated* Correspondence: schow@azcc.arizona.edu
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unless otherwise stated.by a feedback mechanism and is directly correlated with
the amount of adipose tissue. Postmenopausal women
with high adiposity produce elevated levels of estrogens,
a mechanism thought to link high adiposity with breast
cancer [1-5]. In addition, high adiposity is associated
with a reduced sex hormone binding globulin (SHBG) in
postmenopausal women [1-4] which results in an
increase in the fraction of bioavailable sex steroid hor-
mones. The Endogenous Hormones and Breast Cancer
Collaborative Group reanalyzed the worldwide data from
nine prospective studies to examine the relationship
between the levels of endogenous sex hormones and
breast cancer risk in postmenopausal women [6]. Thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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concentrations of all sex hormones examined: total estra-
diol, free estradiol, non-SHBG-bound estradiol, estrone,
estrone sulfate, and testosterone. SHBG was associated with
a decrease in breast cancer risk. In addition, studies have
shown that estrogen metabolites vary in estrogenic and
genotoxic potential with 16α-hydroxyestrone (16α-
OHE1) being mitogenic in breast cancer cells whereas
2-hydroxyestrone (2-OHE1) is considered an estrogen
receptor antagonist [7,8]. Some observation studies have
demonstrated a correlation between a low urinary 2-OHE1/
16α-OHE1 ratio and increased breast cancer risk, whereas
others have not shown the same correlation [9,10].
Resveratrol, a phytochemical produced by a restricted
number of plant species in response to stress, has shown
compelling breast cancer preventive activities in pre-
clinical studies. Resveratrol has been shown to suppress
proliferation of both ER-positive and negative breast
cancer cells in cell culture systems [11,12]. It acts as an
estrogen agonist or antagonist depending on the cell
types, estrogen receptor isoform, and the presence of
endogenous estrogens [13,14]. Some but not all studies
showed that resveratrol inhibits aromatase in breast cancer
cells [15,16]. In addition, resveratrol has been shown to
modulate phase I and phase II enzymes involved in the
activation or detoxification of drugs, endogenous hor-
mones and carcinogens in preclinical studies [17-21]. Our
prior clinical study showed that resveratrol taken at 1
gm daily for 4 weeks led to inhibition of the activity of
cytochrome P450 (CYP) 3A4, 2D6, and 2C9 and induc-
tion of CYP1A2 [22]. Because the formation of 2-OHE1
and 16α-OHE1 was primarily catalyzed by CYP 1A2
and 3A4, respectively, changes in CYP isozyme acti-
vities may lead to changes in the balance between mito-
genic and protective estrogen metabolites.
Here, we report a pilot study conducted in postmeno-
pausal women with high body mass index (BMI) to deter-
mine the modulating effects of resveratrol on circulating
sex steroid hormones and estrogen metabolites to evaluate
its potentials for breast cancer prevention.
Methods
Study design
The study was an open label, single-arm intervention trial
in postmenopausal women with high BMI. The primary
endpoint of the study was change in serum estradiol levels.
Secondary endpoints included estrone, testosterone, SHBG,
2-OHE1/16α-OHE1 ratio. Safety of resveratrol intervention
was assessed by reported adverse events, complete blood
count, and comprehensive metabolic panel.
Study drugs
Resveratrol drug product was supplied by Royalmount
Pharma, Inc. through the Division of Cancer Prevention,National Cancer Institute. Resveratrol caplets were ma-
nufactured by Pharmascience Inc. using synthetic resver-
atrol. Resveratrol purity was assessed by HPLC with UV
detection. Each study caplet contains 500 mg resveratrol
plus inert pharmaceutical excipients. The study caplets
were stored at room temperature and protected from
environmental extremes.Study population
We recruited healthy postmenopausal women with
BMI ≥ 25 kg/m2 at study entry. Postmenopausal was
defined as amenorrhea for at least 12 months, or history
of hysterectomy and bilateral salpingo-oophorectomy, or
at least 55 years of age with prior hysterectomy with or
without oophorectomy, or age 35 to 54 with a prior hys-
terectomy without oophorectomy or with a status of
ovaries unknown with documented follicle-stimulating
hormone level demonstrating elevation in postmeno-
pausal range. Participants were required to have normal
liver and renal function. Study exclusion criteria
included invasive cancers within the past 5 years, within
3 months of or concurrent usage of other investigational
agents, a history of allergic reactions attributed to res-
veratrol, uncontrolled acute or chronic diseases, within
3 months of or concurrent usage of hormonal therapy,
selective estrogen-receptor modulators or aromatase
inhibitors, regular usage of estrogenic supplements, or
concurrent use of anti-diabetic drugs, warfarin or pheny-
toin. The study was approved by the University of
Arizona Human Subjects Protection Program. Written
informed consent was obtained from all participants.Study procedures
During the initial visit, consented study subjects under-
went medical history evaluation and had a fasting blood
sample collected for complete blood count and compre-
hensive metabolic panel. Eligible subjects underwent a
minimum of 2 weeks of washout in which they were
required to limit resveratrol containing foods and prod-
ucts including wine (red and white), peanuts, mulberries,
grapes (seeds, skin, stalks), cranberries, blueberries,
huckleberries, or any food containing these ingredients.
After the washout period, subjects returned to the clinic
for the collection of a fasting blood sample that was used
to measure baseline serum hormone levels and study
agent levels. Participants were instructed to collect a
morning urine void for three consecutive mornings
including the morning of the scheduled baseline visit.
The urine samples were kept at room temperature be-
fore they were brought to the clinic, typically around
48 hours since the initial collection. The urine collection
was used for baseline urinary estrogen metabolite
analyses. Collected serum and urine samples were stored
Table 1 Demographic characteristics of study subjects
who completed the 12-wk intervention period (n =34)
Age at Enrollment, yr 58 ± 8a
Race (White/African American/Mixed) 32/1/1
Ethnicity (Hispanic/Non-Hispanic) 5/29
BMI, mean ± SD, kg/m2
Baseline 32.9 ± 6.0
Post-intervention 32.6 ± 6.3 P = 0.16b
Weight, mean ± SD, kg
Baseline 91.1 ± 18.0
Post-intervention 90.3 ± 19.6 P = 0.24b
aData are presented as mean ± SD.
bDerived from a paired t-test for the change from baseline.
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minimal effects on the analytes of interest.
Following the completion of the baseline sample
collection, subjects took 1 gm dose of resveratrol once a
day (two 500 mg caplets QD) with food for 12 weeks
and continued to limit resveratrol containing foods and
products. At week 6, subjects returned to have a blood
sample collected for study agent level analysis, return
unused pills for a pill count, and review the side effect
diary with study staff.
Subjects returned at the end of the 12-week interven-
tion to return unused drugs and review the side effect
diary with study staff. A fasting blood sample was
collected for clinical labs, post-intervention serum
hormone and study agent level analyses. Three morning
urine voids were collected for post-intervention urinary
estrogen metabolite analyses. Following the resveratrol
intervention, study participants were followed for
2 weeks for any adverse reactions.
Safety of resveratrol intervention was assessed by
reported adverse events and clinical labs. Adverse events
were graded using NCI Common Terminology Criteria
for Adverse Events (CTCAE) version 4.0.
Serum estradiol and estrone concentrations were mea-
sured by a sensitive and specific liquid chromatography-
tandem mass spectrometry assay [23] with minor
modifications. Serum testosterone concentrations were
measured by a sensitive and specific liquid chromatography-
tandem mass spectrometry assay [24] with minor modi-
fications to improve assay specificity. SHBG was mea-
sured using an ELISA based immunoassay (GenWay
Biotech, Inc.). Urinary 2-OHE1 and 16α-OHE1 were
determined using an ELISA based immunoassay
(Immuna Care Corp.).
Plasma resveratrol and metabolite concentrations were
determined using a published HPLC method with UV
detection [25]. Plasma concentrations of resveratrol
metabolites were estimated based on the calibration
curve established with resveratrol standard. The iden-
tity of resveratrol and its metabolites was confirmed by
HPLC in tandem with mass spectrometry by monitor-
ing the parent/product ion transitions of resveratrol
and metabolites [25].
Statistical analysis
Descriptive statistics, e.g. mean and standard deviation,
were calculated for each of the endpoints. A two-sided
paired t test was performed to test if the percent change
from baseline to post-intervention in each of the end-
points is significantly different from zero. Because of the
exploratory nature, analyses of these endpoints were not
corrected for multiple comparisons. Comparison of res-
veratrol/metabolite levels between the mid-study and
post-interventions visits was achieved by a linear mixedeffects model with a random intercept and adjustment
for elapsed time from the prior dose. Descriptive statis-
tics was performed on the type and frequency of all
adverse events.
Results
Forty-six subjects were consented between June 2011
and March 2012 with six found to not meet all inclusion
criteria. Forty subjects initiated the resveratrol interven-
tion with six withdrawn early due to adverse events.
Safety data were analyzed on all subjects who initiated
the resveratrol intervention (n = 40). Systemic hormone
and estrogen metabolite data were analyzed on subjects
who completed 12 weeks of resveratrol intervention
(n = 34). Table 1 summarizes the demographics of study
subjects who completed the 12-wk intervention. The
average age was 58 ± 8 years. The average BMI and body
weight was 32.9 ± 6.0 kg/m2 and 91.1 ± 18.0 kg, respec-
tively, at baseline and was 32.6 ± 6.3 kg/m2 and 90.3 ±
19.6 kg, respectively, post-intervention. Participants took
an average of 95% of the assigned pills.
Table 2 summarizes the baseline and post-intervention
circulating levels of sex steroid hormones and estrogen
metabolites. The mean baseline serum concentrations of
estradiol, estrone, and testosterone were 12.3 ± 20.7 pg/ml,
26.1 ± 12.7 pg/ml, 0.18 ± 0.11 ng/ml, respectively. Resvera-
trol intervention did not result in significant changes in
these sex steroid hormones. The mean baseline SHBG
concentrations were 42.1 ± 17.6 nmol/L. Resveratrol inter-
vention induced an average of 10% increase in serum
SHBG concentrations (p < 0.01). The mean baseline
urinary 2-OHE1, 16α-OHE1, 2-OHE1/16α-OHE1 were
9.5 ± 8.8 ng/mg creatinine, 6.6 ± 6.1 ng/mg creatinine,
and 1.7 ± 1.4, respectively. Resveratrol intervention
resulted in a 73.2% increase in urinary 2-hydroxyestrone
(2-OHE1) levels (p < 0.01), leading to an 84.5% increase
in urinary 2-OHE1/16α-OHE1 ratio (p < 0.01).
Resveratrol and metabolites were not detectable in any of
the baseline plasma samples. Resveratrol and metabolites
Table 2 Summary of baseline and post-intervention systemic sex steroid hormones and estrogen metabolites (n = 34)
Sex steroid hormones Baseline Post-intervention % change Pb
Estradiol, pg/ml 12.3 ± 20.7a 15.5 ± 34.9 22.4 ± 178 0.47
Estrone, pg/ml 26.1 ± 12.7 25.8 ± 14.3 1.4 ± 38.3 0.83
Testosterone, ng/ml 0.18 ± 0.11 0.18 ± 0.12 −0.85 ± 27.2 0.86
SHBG, nmol/L 42.1 ± 17.6 45.3 ± 18.0 10.0 ± 17.8 <0.01
2-OHE1, ng/mg creatinine 9.5 ± 8.8 13.8 ± 8.75 73.2 ± 132 <0.01
16α-OHE1, ng/mg creatinine 6.6 ± 6.1 6.6 ± 3.0 15.9 ± 51.0 0.08
2-OHE1/16α-OHE1 ratio 1.7 ± 1.4 2.7 ± 2.7 84.5 ± 175 <0.01
aData are presented as mean ± SD.
bDerived from a paired t-test for % change from baseline to post-intervention.
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study and post-intervention visits are shown in Figure 1.
The average elapsed time since the prior dose was 965 ±
381 and 818 ± 217 minutes, respectively, for the mid-study
and post-intervention samples. Resveratrol was not de-
tected (assay detection limit of 80 pg/ml) in these samples
while the resveratrol sulfate and/or glucuronide conjugates
were present at high concentrations. Levels of the resvera-
trol metabolites were similar in mid-study and post inter-
vention samples.
Table 3 summarizes AEs observed in study participants
after initiation of the resveratrol intervention. One partici-
pant had asymptomatic Grade 4 elevation in hepatic ALT
and AST enzymes at the end of 3-month agent interven-
tion. The participant had a normal hepatitis panel as part
of the evaluation of this liver test abnormality and
returned every 2–3 weeks for follow-up blood tests for the
hepatic panel. The elevated hepatic enzymes returned to
normal after less than 3 months of follow-up. Six subjects
































































Figure 1 Resveratrol and metabolites concentrations in the
plasma samples collected at mid-study and post-intervention
visits. Plots illustrate the median, 25th, and 75th percentiles as
vertical boxes with 10th and 90th percentiles as error bars.adverse events; two after 12 and 33 days, respectively, due
to Grade 3 skin rash, one after 66 days due to Grade 2
diarrhea, one after 10 days due to Grade 2 allergic re-
action, one after 39 days due to Grade 2 constipation, and
one after one dose due to Grade 2 diarrhea and Grade 1
shortness of breath and wheezing. The remaining AEs
were transient and were Grade 1 or 2 events. The most
common adverse events were diarrhea and dyslipidemia.
Diarrhea was reported in 12 subjects (30%). Increased
total cholesterol was observed in 11 subjects (27.5%) with
increased LDL, VLDL, and cholesterol/HDL ratio in 7
(17.5%), 4 (10%), 3 (7.5%) subjects, , respectively. Increased
triglycerides were observed in 6 (15%) subjects.
Discussion
Overweight and obesity are associated with an increased
risk for postmenopausal breast cancer and poor disease
outcome (reviewed by [26,27]). The increased risk is par-
tially determined by several hormone-related factors. To
the best of our knowledge, our study is the first to report
the clinical activity of resveratrol on circulating sex ster-
oid hormones and estrogen metabolites. The baseline
levels of sex steroid hormones and estrogen metabolites
were similar to those reported in postmenopausal
women in a similar BMI range [4,9,10]. We showed that
1 gm of resveratrol daily for 12 weeks did not alter the
serum estrogen and testosterone concentrations in post-
menopausal women with high adiposity but significantly
increased the concentrations of SHBG, which has been
inversely associated to breast cancer risk [6]. We did not
observe any significant changes in serum insulin levels
(data not shown) and body weight, two major factors
known to influence the blood levels of SHBG [28]. Fu-
ture randomized, controlled trials are needed to confirm
the effect of resveratrol on SHBG. Because SHBG is the
main transport binding protein for circulating sex ster-
oid hormones, it has been suggested that elevation in
SHBG could lead to a decrease in bioavailable sex ster-
oid hormones and their associated bioactivity. We calcu-
lated the hormone fractions based on the law of mass
action [29] and found that resveratrol intervention did
Table 3 Summary of adverse events observed in study
participants after initiation of the resveratrol
intervention (n = 40)
Grade 1a Grade 2 Grade 3 Grade 4
Blood disorders
Anemia 1b 0 0 0
Ear disorders
Tinnitus 1 0 0 0
Eye disorders
Dry eye 1 0 0 0
Gastrointestinal disorders
Diarrhea 6 6 0 0
Dyspepsia 2 1 0 0
Constipation 2 1 0 0
Food poisoning 0 3 0 0
Flatulence 2 0 0 0
Abdominal pain 0 1 0 0
Gastroesophageal reflux 0 1 0 0
Nausea 0 1 0 0
Vomiting 0 1 0 0
Stomach pain 0 1 0 0
Intestinal distress 1 0 0 0
General disorders
Flu-like symptoms 0 3 0 0
Irritability 1 0 0 0
Immune system disorders
Allergic reaction 0 1 0 0
Allergic rhinitis 0 1 0 0
Infections
Upper respiratory infection 0 5 0 0
Sinusitis 0 3 0 0
Urinary tract infection 0 1 0 0
Cold sore on lip 1 1 0 0
Bronchial infection 0 1 0 0
Cold sore in mouth 0 1 0 0
Investigations
↑ Total cholesterol 10 1 0 0
↑ LDL 7 0 0 0
↑ Triglycerides 4 2 0 0
↑ VLDL 4 0 0 0
↑ Cholesterol/HDL ratio 3 0 0 0
↓ HDL 2 0 0 0
↑ non-HDL 1 0 0 0
↑Alanine aminotransferase 2 0 0 1
↑Aspartate aminotransferase 1 0 0 1
Table 3 Summary of adverse events observed in study
participants after initiation of the resveratrol
intervention (n = 40) (Continued)
Metabolism and nutrition disorders
↑ Fasting glucose 4 0 0 0
Appetite change 2 0 0 0
Hypokalemia 1 0 0 0
Musculoskeletal and connective tissue disorders
Myalgia 0 1 0 0
Back pain 0 1 0 0
Neck pain 0 1 0 0
Arthralgia 0 1 0 0
Swollen knee 0 1 0 0
Body aches 1 0 0 0
Leg pain 1 0 0 0
Neoplasms
Ganglion cyst 1 0 0 0
Nervous system disorders
Headache 4 3 0 0
Vivid dreams 2 0 0 0
Dysesthesia 1 0 0 0
Dysgeusia 1 0 0 0
Weird dreams 1 0 0 0
Psychiatric disorders
Insomnia 1 1 0 0
Renal and urinary disorders
Urinary incontinence 0 1 0 0
Bladder spasm 1 0 0 0
Urinary frequency 1 0 0 0
Reproductive system disorders
Pelvic pain 1 0 0 0
Respiratory, thoracic and mediastinal disorders
Dyspnea 2 0 0 0
Laryngitis 0 1 0 0
Sore throat 0 1 0 0
Wheezing 1 0 0 0
Skin and subcutaneous tissue disorders
Dry skin 3 0 0 0
Rash, maculo-papular 0 0 2 0
Rash, other 1 0 0 0
Vascular disorders
Hot flashes 3 1 0 0
aGraded using CTCAE version 4.0.
bNumber of subjects experienced the event.
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but decreased the levels of bioavailable testosterone
(from 0.087 ± 0.066 to 0.076 ± 0.050 ng/ml, p = 0.03).
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resveratrol-induced hormonal changes on breast cancer
risk modulation.
Interestingly, our study showed that 1 gm of resvera-
trol daily for 12 weeks resulted in a significant increase
in urinary 2-OHE1 levels leading to a favorable change
in urinary 2-OHE1/16α-OHE1 ratio. The formation of 2-
OHE1 and 16α-OHE1 was primarily catalyzed by cyto-
chrome P450 (CYP) 1A2 and 3A4, respectively. The
observed changes in estrogen metabolism is consistent
with our prior clinical study that showed an induction of
1A2 and inhibition of 3A4 activity after 4 weeks of 1 gm
daily resveratrol dosing [22]. Prior studies have shown
that putative cancer preventive compounds derived
from cruciferous vegetables, indole-3-carbinol and 3,3′-
diindolylmethane, also increased the urinary 2-OHE1/16α-
OHE1 ratio [30-32]. Some observation studies have
demonstrated a correlation between a low urinary 2-
OHE1/16α-OHE1 ratio and increased breast cancer risk,
whereas others have not shown the same correlation
[9,10]. Further research is needed to evaluate whether
resveratrol-induced changes in estrogen metabolism would
contribute to breast cancer risk modulation.
The resveratrol dose and product used in our study
has previously been shown to be safe and well tolerated
up to 4 weeks in healthy adults [22]. In this study of
overweight or obese postmenopausal women, six sub-
jects withdrew early after taking resveratrol for 1–66
days due to adverse events including diarrhea, constipa-
tion, skin rash, allergic reaction, and shortness of breath.
One participant had asymptomatic Grade 4 ALT and
AST elevation at the post-intervention visit which nor-
malized after less than 3 months of follow-up and was
considered possibly related to resveratrol intervention.
The common reported adverse events were diarrhea and
dyslipidemia. Diarrhea has been reported in previous
clinical studies of resveratrol [22,33]. It is not known
whether the unfavorable change in the lipid profile is
related to the resveratrol intervention in the study popu-
lation. A recent study showed that 1, 1.5, or 2 g of
resveratrol daily for 4 weeks did not change the fasting
lipid profile in older overweight/obese adults with
impaired glucose tolerance [34] whereas another study
showed that supplementation of 1 g resveratrol daily for
45 days improved the HDL levels in diabetic patients [35].
Our study has a number of limitations. First, we have
designed this study as a pilot project to assess changes
in systemic sex steroid hormones before proceeding to
larger trials. Further clinical investigation should include
a control arm to minimize potential confounders (such as
changes in diet and physical activity) in single arm studies.
In addition, we have observed a large inter-individual vari-
ation in serum estradiol and estrone levels. Larger sample
sizes may be needed to observe a significant effect fromthe supplementation on these measurements. In addition,
future studies should consider measurements of serum
hormone levels (such as follicle-stimulating hormone and
luteinizing hormone) to confirm postmenopausal status
for study entry.
Conclusions
We conclude that in postmenopausal women with high
BMI, daily 1 gm dose of resveratrol had favorable effects
on SHBG and estrogen metabolites. Further placebo-
controlled studies are needed to confirm our findings on
these hormone-related breast cancer risk factors and the
attribution of the adverse effects observed in the study
population.
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